Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report.

Susanne Gahr; Till Wissniowski; Steffen Zopf; Deike Strobel; Anette Pustowka; Matthias Ocker

doi:10.7150/jca.4211

Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report.

Susanne Gahr (First author), Till Wissniowski, Steffen Zopf, Deike Strobel, Anette Pustowka, Matthias Ocker

Department of Internal Medicine III, Division of Respiratory Medicine, Allergology and Sleep Medicine

Research output: Contribution to journal › Original Article › peer-review

21 Citations (Web of Science)

Original language	English
Pages (from-to)	158-165
Journal	JOURNAL OF CANCER
Volume	3
DOIs	https://doi.org/10.7150/jca.4211
Publication status	Published - 2012

Keywords

GASTROINTESTINAL TUMOR-CELLS
HISTONE-DEACETYLASE
CANCER-CELLS
RAF/MEK/ERK PATHWAY
TARGETED THERAPIES
ANTITUMOR-ACTIVITY
CD95 ACTIVATION
HEPATOMA-CELLS
ANGIOGENESIS
VORINOSTAT

Access to Document

10.7150/jca.4211

Cite this

Gahr, S., Wissniowski, T., Zopf, S., Strobel, D., Pustowka, A., & Ocker, M. (2012). Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report. JOURNAL OF CANCER, 3, 158-165. https://doi.org/10.7150/jca.4211

@article{62d9270c5d5a4be0875ef7156b2a8324,

title = "Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report.",

keywords = "GASTROINTESTINAL TUMOR-CELLS, HISTONE-DEACETYLASE, CANCER-CELLS, RAF/MEK/ERK PATHWAY, TARGETED THERAPIES, ANTITUMOR-ACTIVITY, CD95 ACTIVATION, HEPATOMA-CELLS, ANGIOGENESIS, VORINOSTAT",

author = "Susanne Gahr and Till Wissniowski and Steffen Zopf and Deike Strobel and Anette Pustowka and Matthias Ocker",

note = "Gahr: Klinikum Nuremberg Nord, Department of Pneumology, Nuremberg, Germany",

year = "2012",

doi = "10.7150/jca.4211",

language = "English",

volume = "3",

pages = "158--165",

journal = "JOURNAL OF CANCER",

issn = "1837-9664",

}

Gahr, S, Wissniowski, T, Zopf, S, Strobel, D, Pustowka, A & Ocker, M 2012, 'Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report.', JOURNAL OF CANCER, vol. 3, pp. 158-165. https://doi.org/10.7150/jca.4211

Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report. / Gahr, Susanne (First author); Wissniowski, Till; Zopf, Steffen et al.
In: JOURNAL OF CANCER, Vol. 3, 2012, p. 158-165.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report.

AU - Gahr, Susanne

AU - Wissniowski, Till

AU - Zopf, Steffen

AU - Strobel, Deike

AU - Pustowka, Anette

AU - Ocker, Matthias

N1 - Gahr: Klinikum Nuremberg Nord, Department of Pneumology, Nuremberg, Germany

PY - 2012

Y1 - 2012

KW - GASTROINTESTINAL TUMOR-CELLS

KW - HISTONE-DEACETYLASE

KW - CANCER-CELLS

KW - RAF/MEK/ERK PATHWAY

KW - TARGETED THERAPIES

KW - ANTITUMOR-ACTIVITY

KW - CD95 ACTIVATION

KW - HEPATOMA-CELLS

KW - ANGIOGENESIS

KW - VORINOSTAT

U2 - 10.7150/jca.4211

DO - 10.7150/jca.4211

M3 - Original Article

C2 - 22514558

SN - 1837-9664

VL - 3

SP - 158

EP - 165

JO - JOURNAL OF CANCER

JF - JOURNAL OF CANCER

ER -